Semler Scientific (SMLR) Registration Filing summary

Company overview and business model

• Provides technology solutions to improve clinical effectiveness and efficiency for healthcare providers, focusing on chronic disease evaluation and treatment.

• Main product, QuantaFlo, is FDA-cleared for measuring arterial blood flow to aid in diagnosing cardiovascular diseases, with ongoing efforts to expand its use.

• Recently adopted bitcoin as its primary treasury reserve asset, holding 828 bitcoins as of June 6, 2024, acquired for $57 million.

• Seeks to position bitcoin as a reliable store of value and does not plan to purchase other cryptocurrencies.

Financial performance and metrics

• Stock price has shown significant volatility, ranging from $21.03 to $51.54 per share in 2024.

• Volatility attributed to lower-than-expected Q1 2024 results and the announcement of the bitcoin strategy.

• As of March 31, 2024, 6,919,771 shares were outstanding, with additional options and shares available under equity plans.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for general corporate purposes, including working capital, R&D, capital expenditures, potential acquisitions, and notably, the acquisition of bitcoin.

• Management retains broad discretion over allocation of proceeds.